OCI NV (OCI)
Euronext Amsterdam · Netherlands · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 4.102 |
|---|---|
| 52-week range | 2.550 – 4.240 |
| Return, 1 month / 3 months | −0.2% / +0.8% |
| Return, 1 year / 3 years | +20.6% / +6.5% |
| Trend | Uptrend |
| RSI (14) | 46 |
| Volatility (1 year) | 36.4% |
| Worst drawdown (1 year) | -24.6% |
| Average daily value traded | 1.16M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
OCI produces nitrogen fertilizers and industrial chemicals, supplying farmers and industrial customers with ammonia, urea, nitric acid, methanol and melamine. Its operations span production sites in Europe, North Africa, the Middle East and the Americas, and the company is based in the Netherlands. It serves agricultural markets through fertilizer products and also supplies methanol and other chemicals to industrial users, with natural gas and other raw materials feeding its manufacturing plants.
On this site OCI NV appears as a stock on the Euronext Amsterdam (Netherlands), code OCI, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
OCI NV (OCI) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 4.102 on 22 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 38 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.6% and over the last three months it rose 0.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.3% | ||
| From 52-week high | -1.6% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.8% | ||
| 6-month return | 11.9% | ||
| 12-month return, skipping the last month | 20.9% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.6% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 1.16M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | −0.2% |
| 3 months | +0.8% |
| 6 months | +11.9% |
| 1 year | +20.6% |
| 3 years | +6.5% |
| 5 years | +30.6% |
Signals
| 50-day / 200-day average | 4.096 / 3.788 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.047 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Aug 2025 | EUR 2.8380 |
| 15 Apr 2025 | EUR 4.1840 |
| 28 Oct 2024 | EUR 14.5000 |
| 26 Oct 2023 | EUR 0.8500 |
| 20 Apr 2023 | EUR 3.5000 |
| 26 Oct 2022 | EUR 3.5500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.